Forget the FDA Delay: 3 Reasons Exelixis Is Still a BuyThe Motley Fool · 1 day ago
Exelixis Rises with Earnings on TapFXEmpire · 2 days ago
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research · 3 days ago
Why Exelixis (EXEL) is a Top Growth Stock for the Long-TermZacks Investment Research · Oct 16, 2026
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates AgainZacks Investment Research · Oct 15, 2026
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmGuruFocus · Oct 12, 2026Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.85 | $0.91 | Beat |
| May 5, 2026 | $0.77 | $0.87 | Beat |
| Feb 10, 2026 | $0.77 | $0.94 | Beat |
| Nov 4, 2025 | $0.69 | $0.78 | Beat |
| Jul 28, 2025 | $0.65 | $0.75 | Beat |
| May 13, 2025 | $0.36 | $0.62 | Beat |